Copanlisib population pharmacokinetics from phase I–III studies and exposure–response relationships in combination with rituximab von Morcos, Peter N., Moss, Jonathan, Austin, Rupert, Hiemeyer, Florian, Zinzani, Pier Luigi, Beckert, Vita, Mongay Soler, Lidia, Childs, Barrett H., Garmann, Dirk

Volltext

Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3... von Matasar, Matthew J, Capra, Marcelo, Özcan, Muhit, Lv, Fangfang, Li, Wei, Yañez, Eduardo, Sapunarova, Katya, Lin, Tongyu, Jin, Jie, Jurczak, Wojciech, Hamed, Aryan, Wang, Ming-Chung, Baker, Ross, Bondarenko, Igor, Zhang, Qingyuan, Feng, Jifeng, Geissler, Klaus, Lazaroiu, Mihaela, Saydam, Guray, Szomor, Árpád, Bouabdallah, Krimo, Galiulin, Rinat, Uchida, Toshiki, Soler, Lidia Mongay, Cao, Anjun, Hiemeyer, Florian, Mehra, Aruna, Childs, Barrett H, Shi, Yuankai, Zinzani, Pier Luigi

Volltext

Population Pharmacokinetics and Exposure-Response Analyses from Phase I-III Studies Support Copanlisib Dose Selection in Relapsed Indolent Non-Hodgkin Lymphoma von Moss, Jonathan, Garmann, Dirk, Austin, Rupert, Hiemeyer, Florian, Matasar, Matthew J., Zinzani, Pier Luigi, Beckert, Vita, Mongay Soler, Lidia, Childs, Barrett H., Morcos, Peter N.

Volltext

Pooled Safety Analysis from Phase I-III Studies for Patients with Hematological Malignancies Treated with the PI3K Inhibitor Copanlisib von Zinzani, Pier Luigi, Özcan, Muhit, Capra, Marcelo, Santoro, Armando, Panayiotidis, Panayiotis, Bouabdallah, Krimo, Jurczak, Wojciech, Phelps, Charles, Hiemeyer, Florian JR, Mongay Soler, Lidia, Garcia-Vargas, Jose, Childs, Barrett H., Lenz, Georg, Matasar, Matthew J., Dreyling, Martin

Volltext

Copanlisib + rituximab versus rituximab + placebo in patients with relapsed follicular (FL) or marginal zone lymphoma (MZL): Subset analysis from the phase III CHRONOS-3 trial von Matasar, Matthew J., Capra, Marcelo, Özcan, Muhit, Lv, Fangfang, Li, Wei, Yanez, Eduardo, Sapunarova, Katya, Lin, Tongyu, Jin, Jie, Jurczak, Wojciech, Hamed, Aryan, Wang, Ming-Chung, Mongay Soler, Lidia, Cao, Anjun, Phelps, Charles, Childs, Barrett H., Shi, Yuankai, Zinzani, Pier Luigi

Volltext

Duration of Objective Responses for Patients with Indolent Non-Hodgkin Lymphoma Discontinuing Treatment before Progression: Analysis from the Phase III Chronos-3 Trial Comparing Co... von Matasar, Matthew J., Capra, Marcelo, Özcan, Muhit, Lv, Fangfang, Li, Wei, Yañez, Eduardo, Sapunarova, Katya, Lin, Tongyu, Jin, Jie, Jurczak, Wojciech, Hamed, Aryan, Wang, Ming-Chung, Mongay Soler, Lidia, Cao, Anjun, Hiemeyer, Florian, Childs, Barrett H, Shi, Yuankai, Zinzani, Pier Luigi Luigi

Volltext

Abstract P239: Safety and efficacy of copanlisib in combination with nivolumab: A phase Ib study in patients with advanced solid tumors von Carneiro, Benedito A., Jotte, Robert, Gabrail, Nashat, Hamid, Omid, Huang, Funan, Chaturvedi, Shalini, Herpers, Matthias, Soler, Lidia Mongay, Childs, Barrett H., Hansen, Aaron

Volltext

Abstract CT001: CHRONOS-3: Randomized Phase III study of copanlisib plus rituximab vs rituximab/placebo in relapsed indolent non-Hodgkin lymphoma (iNHL) von Matasar, Matthew J., Capra, Marcelo, Özcan, Muhit, Lv, Fangfang, Li, Wei, Yañez, Eduardo, Sapunarova, Katya, Lin, Tongyu, Jin, Jie, Jurczak, Wojciech, Hamed, Aryan, Wang, Ming-Chung, Baker, Ross, Bondarenko, Igor, Zhang, Qingyuan, Feng, Jifeng, Geissler, Klaus, Lazaroiu, Mihaela, Saydam, Guray, Szomor, Árpád, Bouabdallah, Krimo, Galiulin, Rinat, Uchida, Toshiki, Soler, Lidia Mongay, Cao, Anjun, Hiemeyer, Florian, Mehra, Aruna, Childs, Barrett H., Shi, Yuankai, Zinzani, Pier Luigi

Volltext

Abstract LB523: Biomarker assessment of PTEN protein expression and gene expression profiling (GEP) in a phase III study of copanlisib in combination with rituximab in patients wit... von Chaturvedi, Shalini, Schulz, Anke, Soler, Lidia Mongay, Childs, Barrett H., Matasar, Matthew, Zinzani, Pier Luigi

Volltext

Abstract CT082: Next-generation sequencing (NGS) and cytokine assessment from a phase III study of copanlisib in combination with rituximab in patients with indolent non-Hodgkin ly... von Chaturvedi, Shalini, Weispfenning, Anke, Bauer, David, Du, Rong, Descamps, Tine, Bellinvia, Sara, Lunt, Teresa, Soler, Lidia Mongay, Childs, Barrett H., Zinzani, Pier Luigi

Volltext

Abstract A25: Copanlisib population pharmacokinetics (popPK) and exposure-response (ER) in relapsed indolent non-Hodgkin lymphoma (iNHL): Analysis from the 1-year follow-up of the... von Moss, Jonathan, Garmann, Dirk, Austin, Rupert, Hiemeyer, Florian, DeLora, Patricia, Matasar, Matthew J, Zinzani, Pier Luigi, Beckert, Vita, Soler, Lidia Mongay, Childs, Barrett H, Morcos, Peter N

Volltext

Abstract A32: Copanlisib plus rituximab vs placebo plus rituximab in patients with follicular lymphoma: 1-year follow-up of the Phase III, randomized CHRONOS-3 trial von Capra, Marcelo, Lv, Fangfang, Li, Wei, Lin, Tongyu, Yañez, Eduardo, Feng, Jifeng, Hamed, Aryan, Li, Xiaoling, Uchida, Toshiki, Wang, Ming-Chung, Izutsu, Koji, Salar, Antonio, Sapunarova, Katya, Saydam, Guray, Zaucha, Jan, Soler, Lidia Mongay, Chaturvedi, Shalini, Cao, Anjun, Childs, Barrett H, Zinzani, Pier Luigi, Matasar, Matthew J

Volltext

Interacció p45(SKP2)-CksHs1 i la seva funció en la regulació dels complexes Ciclina A/CDK2 del cicle cel·lular von Mongay Soler, Lidia

Volltext bestellen

Interacció p45(SKP2)-CksHs1 i la seva funció en la regulació dels complexes Ciclina A/CDK2 del cicle cel·lular von Mongay Soler, Lidia

Volltext bestellen